Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.54
LIFE's Cash to Debt is ranked lower than
74% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. LIFE: 1.54 )
Ranked among companies with meaningful Cash to Debt only.
LIFE' s 10-Year Cash to Debt Range
Min: 1.54  Med: 3.42 Max: 5.29
Current: 1.54
1.54
5.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA (%) -135.67
LIFE's ROA (%) is ranked lower than
88% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. LIFE: -135.67 )
Ranked among companies with meaningful ROA (%) only.
LIFE' s 10-Year ROA (%) Range
Min: -80.59  Med: -80.59 Max: -80.59
Current: -135.67
ROC (Joel Greenblatt) (%) -4137.04
LIFE's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. LIFE: -4137.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LIFE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2447.17  Med: -2447.17 Max: -2447.17
Current: -4137.04
» LIFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

LIFE Guru Trades in Q3 2013

Louis Moore Bacon 6,767 sh (New)
Jim Simons 1,857,897 sh (+207.40%)
Diamond Hill Capital 96,693 sh (+18.28%)
Jeremy Grantham 444,698 sh (+2.23%)
Mario Gabelli 1,334,898 sh (+1.78%)
First Pacific Advisors 581,198 sh (unchged)
Murray Stahl Sold Out
PRIMECAP Management 13,127,442 sh (-1.59%)
Steven Cohen 4,830 sh (-12.69%)
First Eagle Investment 200,000 sh (-56.11%)
Larry Robbins 4,251,124 sh (-58.35%)
Joel Greenblatt 3,541 sh (-67.32%)
John Paulson 181,053 sh (-85.90%)
» More
Q4 2013

LIFE Guru Trades in Q4 2013

Joel Greenblatt 14,885 sh (+320.36%)
Jim Simons 3,241,897 sh (+74.49%)
Steven Cohen 6,307 sh (+30.58%)
Diamond Hill Capital 97,280 sh (+0.61%)
John Paulson 89,657 sh (unchged)
PRIMECAP Management 12,827,575 sh (-2.28%)
Louis Moore Bacon 6,612 sh (-2.29%)
Mario Gabelli 1,159,098 sh (-13.17%)
Larry Robbins 2,749,798 sh (-35.32%)
First Pacific Advisors 288,198 sh (-50.41%)
John Paulson 89,657 sh (-50.48%)
First Eagle Investment 72,600 sh (-63.70%)
Jeremy Grantham 81,598 sh (-81.65%)
» More
Q1 2014

LIFE Guru Trades in Q1 2014

PRIMECAP Management Sold Out
First Eagle Investment Sold Out
Joel Greenblatt Sold Out
John Paulson Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Diamond Hill Capital Sold Out
First Pacific Advisors Sold Out
Larry Robbins Sold Out
Mario Gabelli Sold Out
Larry Robbins 2,749,798 sh (-76.18%)
» More
Q2 2015

LIFE Guru Trades in Q2 2015

RS Investment Management 669,237 sh (New)
RS Investment Management 669,237 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with LIFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on aTyr Pharma Inc

Mario Gabelli Comments on Life Technologies Corp - Apr 30, 2014

Life Technologies Corp. (LIFE) is a California based biotechnology company focused on reagents and scientific instruments. On April 15, 2013, Thermo Fisher Scientific announced it would acquire Life for $76 cash per share in a $13.6 billion merger. Shareholders approved the deal in August of 2013 and the merger was completed on February 3, 2014, after regulators in the U.S., European Union, and China approved it. As part of the merger agreement, the Fund received an incremental $0.13 per share in the form of a ticking fee, since the deal did not close by January 14, 2014. The Fund's return was 5.92%.

From Mario Gabelli (Trades, Portfolio)'s first quarter 2014 ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Ratios

vs
industry
vs
history
P/B 29.55
LIFE's P/B is ranked lower than
96% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. LIFE: 29.55 )
Ranked among companies with meaningful P/B only.
LIFE' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 42.54
Current: 29.55
0
42.54
Current Ratio 1.69
LIFE's Current Ratio is ranked lower than
78% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. LIFE: 1.69 )
Ranked among companies with meaningful Current Ratio only.
LIFE' s 10-Year Current Ratio Range
Min: 1.69  Med: 4.40 Max: 7.11
Current: 1.69
1.69
7.11
Quick Ratio 1.69
LIFE's Quick Ratio is ranked lower than
74% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. LIFE: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
LIFE' s 10-Year Quick Ratio Range
Min: 1.69  Med: 4.40 Max: 7.11
Current: 1.69
1.69
7.11

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1448.00
LIFE's Price/Net Cash is ranked lower than
240% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. LIFE: 1448.00 )
Ranked among companies with meaningful Price/Net Cash only.
LIFE' s 10-Year Price/Net Cash Range
Min: 0  Med: 0.00 Max: 0
Current: 1448
Price/Net Current Asset Value 181.00
LIFE's Price/Net Current Asset Value is ranked lower than
200% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. LIFE: 181.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LIFE' s 10-Year Price/Net Current Asset Value Range
Min: 0  Med: 0.00 Max: 0
Current: 181
Price/Tangible Book 29.55
LIFE's Price/Tangible Book is ranked lower than
93% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. LIFE: 29.55 )
Ranked among companies with meaningful Price/Tangible Book only.
LIFE' s 10-Year Price/Tangible Book Range
Min: 0  Med: 0.00 Max: 0
Current: 29.55

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, ENZ, IDXX » details
aTyr Pharma Inc was incorporated in the state of Delaware on September 8, 2005. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The Company is currently conducting a multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD in the European Union. This randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple intravenous doses of Resolaris in adults with FSHD. Its initial therapeutic efforts target severe, rare disease indications in which patients suffer from the immune-related consequences of their genetic disease. It contracts with third parties for the manufacturing and testing of its product candidates for preclinical studies and clinical trials and intend to do so in the future. It does not own or operate manufacturing facilities for the production of clinical quantities of its product candidates. Government authorities in the United States, including federal, state, and local authorities, and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical and biological products, such as those it is developing.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK